D. Sugimoto

发表

The effects of high‐dose amlodipine/benazepril combination therapies on blood pressure reduction in patients not adequately controlled with amlodipine monotherapy

M. Lefkowitz, V. Shi, V. Arora, 2007, Blood pressure. Supplement.

Efficacy of iGlarLixi, a fixed‐ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to HEDIS measurements

V. Aroda, T. Dex, D. Sugimoto, 2018, Diabetes, obesity & metabolism.

Efficacy and safety of coadministration of ezetimibe and simvastatin in African-American patients with primary hypercholesterolemia.

R. Rodney, R. Suresh, E. Veltri, 2006, Journal of the National Medical Association.

The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil.

M. Lefkowitz, M. Weir, M. Houston, 1995, Archives of internal medicine.

A psyllium-enriched cereal for the treatment of hypercholesterolemia in children: a controlled, double-blind, crossover study.

M. Davidson, J. H. Burns, D. Sugimoto, 1996, The American journal of clinical nutrition.

A placebo-controlled, dose-response study of dexfenfluramine in the treatment of obese patients

T. Marbury, S. Zellner, A. Krosnick, 1996 .

Efficacy and Safety of Semaglutide Once-Weekly vs. Placebo as Add-on to Basal Insulin Alone or in Combination with Metformin in Subjects with Type 2 Diabetes (SUSTAIN 5)

H. Rodbard, E. Araki, P. Norwood, 2016 .

Cardiometabolic risk factors efficacy of semaglutide in the STEP program

N. Skolnik, D. Sugimoto, Anastassia Amaro, 2022, Postgraduate medicine.

The TRINITY Study: distribution of systolic blood pressure reductions

M. Melino, S. Chrysant, James Lee, 2013, Integrated blood pressure control.

Efficacy and safety of semaglutide for weight management: evidence from the STEP program

S. Wharton, D. Sugimoto, Anastassia Amaro, 2022, Postgraduate medicine.

Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial

H. Rodbard, E. Araki, P. Norwood, 2018, The Journal of clinical endocrinology and metabolism.

Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial

W. Garvey, G. Mingrone, D. Skovgaard, 2020, Diabetes Care.

Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial

T. Wadden, P. Auerbach, D. Rubino, 2020, Obesity.

IDegLira improves patient‐reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal–bolus therapy

L. Billings, A. Doshi, M. Ranthe, 2019, Diabetes, obesity & metabolism.

Effects of IDegLira (Insulin Degludec/Liraglutide) in Patients with Poorly Controlled Type 2 Diabetes (T2D) with A1C >9%—Analyses from the DUAL Program

J. Frias, S. Bain, D. Sugimoto, 2018, Diabetes.

Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial

T. Wadden, P. Auerbach, D. Rubino, 2020, Obesity Facts.

Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.

C. Kilo, P. Hollander, A. Vlajnic, 2015, Journal of diabetes and its complications.